EAN 2026: New Fintepla data in Dravet Syndrome and LGS - Pharmaceutical Technology

The trial of Fintepla in Dravet Syndrome and LGS was run by researchers at the Brno Epilepsy Centre in Czechia. The trial of Fintepla in Dravet Syndrome and LGS was run by researchers at the Brno Epilepsy Centre in Czechia. Fintepla was first approved by the US Food and Drug Administration (FDA) on 25 June 2020 for the treatment of seizures associated with Dravet syndrome. Credit: Piotr Swat / Shutterstock.com Researchers at the Brno Epilepsy Centre in Czechia announced data from a retrospective, single-centre observational study evaluating the efficacy and safety of UCB’s Fintepla (fenfluramine) in adults living with Dravet…

Source: Pharmaceutical Technology